Saroja Pharma Industries India Limited has submitted its quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ending March 31, 2025. The certificate, issued by M/s. KFIN Technologies Limited, the Registrar and Share Transfer Agent of the company, confirms that the company has complied with all requirements related to the dematerialization and rematerialization of securities during the said period.

Key Details of the Certificate Submission

The certificate was sent to multiple stock exchanges, including the National Stock Exchange of India Limited (NSE), National Securities Depository Limited (NSDL), and Central Depository Services (India) Limited (CDSL). The document serves as a formal compliance declaration that all dematerialized and rematerialized securities of Saroja Pharma during the quarter have been reported to the relevant authorities. This submission ensures that the company remains in good standing with SEBI regulations and continues to maintain transparency in its share transfer process.

The letter was dated April 2, 2025, and has been submitted to the following entities:

• National Stock Exchange of India Limited

• National Securities Depository Limited

• Central Depository Services (India) Limited

Content of the Certificate and Compliance Requirements

As per Regulation 74(5) of the SEBI regulations, the certificate confirms that M/s. KFIN Technologies Limited has provided the necessary details regarding the securities dematerialized and rematerialized during the period from January 1, 2025, to March 31, 2025. The Registrar and Share Transfer Agent of the company, as outlined in the certificate, ensures that the necessary reporting protocols were followed and that the relevant information was duly communicated to all stock exchanges where the company’s shares are listed.

Implications for Saroja Pharma and Shareholders

For Saroja Pharma, this certificate plays a crucial role in maintaining compliance with SEBI’s regulatory framework concerning the dematerialization process of securities. It assures investors and shareholders that the company is following the prescribed regulatory norms and is transparent in its handling of shareholder records. For shareholders, this certificate serves as a confirmation that their shares are properly accounted for in electronic form under dematerialized accounts, which facilitates faster trading and settlement of securities.

Future Compliance and Updates

Saroja Pharma has always adhered to the SEBI regulations, and this certificate is part of their ongoing commitment to ensure legal compliance and provide transparency in the management of their securities. The company will continue to comply with SEBI guidelines and stock exchange regulations to ensure that its shareholders' interests are well protected.

For any future updates on dematerialization or rematerialization of shares, the company will continue to issue similar compliance certificates on a quarterly basis. Shareholders and investors can look forward to regular updates from the company to remain informed about any changes in their shareholding patterns or the status of their securities.

Stay tuned for more updates on Saroja Pharma and its regulatory submissions, ensuring that all corporate actions are in full compliance with SEBI’s guidelines.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.